Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
about
Residual macrovascular risk in 2013: what have we learned?PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Is fenofibrate a reasonable treatment for diabetic microvascular disease?Fibroblast growth factor 23 and incident CKD in type 2 diabetes.Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice.Fenofibrate and the kidney: an overview.Role of dyslipidemia in patients with chronic kidney disease.Demystifying the management of hypertriglyceridaemia.Therapeutic approaches to diabetic nephropathy--beyond the RAS.Safety considerations with fenofibrate/simvastatin combination.Glucose targets for preventing diabetic kidney disease and its progression.Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats.Distinct but complementary contributions of PPAR isotypes to energy homeostasis.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.
P2860
Q26996039-A835B8FE-CA24-4AC6-A544-8D25B733D703Q30241952-42EFC80F-E128-42E7-B01C-4B00BC79788CQ30372692-19F55726-94A5-495A-ACC9-310D0AB65172Q34828731-5CE3C59A-4E93-48B8-AD17-F6ECB11A552FQ37287426-D71A8C58-A297-44A5-BD60-D3B8F94375ECQ38088377-FDED7323-7A8D-473A-BBE5-7DFAB5FA138AQ38120646-4EB30E85-ECA6-4CCA-A5DB-76418EB7DF5BQ38141575-0CF88289-B2EF-4E42-83C1-E53A841CEDC4Q38209811-E55CF438-BB74-42F3-9397-CA42CCC62DB2Q38541832-69767821-E10C-47F3-8E44-B53A5D0FAF52Q38736800-C6115ECE-AF85-4652-AAE6-4D33967677ADQ38856838-3A1EA4BE-9715-4D76-9630-2665892F0F3DQ38911782-8717E591-3B2B-475F-8200-64AFDCE0D5F2Q39214885-E96223AB-D55E-4BAF-BD77-7279D996099EQ48141985-AACFACC8-4F88-43B6-BF41-C17F85C4570F
P2860
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@ast
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@en
type
label
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@ast
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@en
prefLabel
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@ast
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@en
P2093
P2860
P1433
P1476
Fenofibrate-associated changes ...... n Diabetes (ACCORD) experience
@en
P2093
H N Ginsberg
J C Mychaleckyj
J R Crouse
J-A Sperl-Hillen
K Kirchner
P J O'Connor
P2860
P2888
P304
P356
10.1007/S00125-012-2524-2
P577
2012-03-27T00:00:00Z
P5875
P6179
1039707228